Molecular-targeted therapy hypoxia in head and neck squamous cell carcinoma patients (Review)

Adachi,Makoto; Thomas,Ligy

doi:10.3892/mco.2012.17

Molecular-targeted therapy hypoxia in head and neck squamous cell carcinoma patients (Review)

Authors:
- Makoto Adachi
- Ligy Thomas
View Affiliations

Affiliations: Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Published online on: September 3, 2012 https://doi.org/10.3892/mco.2012.17
Pages: 12-14

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite advances in surgical techniques, radiotherapy, and chemotherapy, 5‑year survival in patients with late‑stage head and neck squamous cell carcinoma (HNSCC) have not improved significantly over the past decades. HNSCC tumors are commonly associated with hypoxia, which is characterized by an acute and/or chronic decline in oxygen tension. Hypoxia is an important cancer‑aggravating microenvironmental factor that contributes to malignant behaviors such as acquisition of antiapoptotic ability by cancer cells and tumor progression, invasion, metastasis, and resistance to chemotherapy and radiotherapy. Numerous studies have assessed tumor hypoxia and identified molecular markers that are promising therapeutic targets in HNSCC cases. Moreover, investigators have suggested a number of molecular strategies to target cell processes critical to hypoxia development in HNSCC patients via the direct or indirect regulation of hypoxia‑inducible factor-1α expression in cancer cells. In this review, we described recent advances in the identification and development of molecular-targeted therapy targeting hypoxia in HNSCC patients.

View Figures

View References

1.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin. 60:277–300. 2010.
2.	Choong N and Vokes E: Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin. 58:32–53. 2008.
3.	Karar J and Maity A: Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther. 8:1994–2001. 2009.
4.	Mottram JC: A factor of importance in the radio sensitivity of tumours. Br J Radiol. 9:606–614. 1936.
5.	Thomlinson RH and Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 9:539–549. 1955.
6.	Nordsmark M, Overgaard M and Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 41:31–39. 1996.
7.	Rajendran JG, Mankoff DA, O’Sullivan F, et al: Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F] fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 10:2245–2252. 2004.
8.	Bentzen L, Keiding S, Horsman MR, Falborg L, Hansen SB and Overgaard J: Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography - a study evaluating [18F]fluoro-2-deoxy-D-glucose. Acta Oncol. 39:629–637. 2000.
9.	Cooper RA, Carrington BM, Loncaster JA, et al: Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol. 57:53–59. 2000.
10.	Hoskin PJ, Saunders MI, Goodchild K, Powell ME, Taylor NJ and Baddeley H: Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol. 72:1093–1098. 1999.
11.	Ferreira MB, De Souza JA and Cohen EE: Role of molecular markers in the management of head and neck cancers. Curr Opin Oncol. 23:259–264. 2011.
12.	Melillo G: Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res. 4:601–605. 2006.
13.	Aebersold DM, Burri P, Beer KT, et al: Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61:2911–2916. 2001.
14.	Yeo EJ, Chun YS and Park JW: New anticancer strategies targeting HIF-1. Biochem Pharmacol. 68:1061–1069. 2004.
15.	Semenza GL: Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell. 5:405–406. 2004.
16.	Rohwer N, Lobitz S, Daskalow K, et al: HIF-1alpha determines the metastatic potential of gastric cancer cells. Br J Cancer. 100:772–781. 2009.
17.	Airley RE, Phillips RM, Evans AE, et al: Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: Results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int J Oncol. 26:1477–1484. 2005.
18.	Isa AY, Ward TH, West CM, Slevin NJ and Homer JJ: Hypoxia in head and neck cancer. Br J Radiol. 79:791–798. 2006.
19.	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003.
20.	Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G and Powis G: Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther. 3:233–244. 2004.
21.	Xia Y, Choi HK and Lee K: Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem. 49:24–40. 2012.
22.	Adachi M, Cui C, Dodge CT, Bhayani MK and Lai SY: Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol. Jul 6–2012, (E-pub ahead of print).